Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1968 2
1970 1
1971 3
1972 1
1974 1
1975 1
1976 6
1977 9
1979 4
1980 5
1981 2
1982 5
1983 3
1984 8
1985 3
1986 2
1987 3
1988 2
1989 4
1990 10
1991 6
1992 6
1993 6
1994 6
1995 4
1996 7
1997 7
1998 6
1999 6
2000 8
2001 8
2002 19
2003 13
2004 24
2005 24
2006 21
2007 26
2008 25
2009 25
2010 35
2011 42
2012 44
2013 32
2014 57
2015 62
2016 70
2017 89
2018 88
2019 117
2020 154
2021 185
2022 186
2023 210
2024 248
2025 109

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,826 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Kanetaki
Page 1
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.
Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, Vanden Abeele C, Vesikari T, Watanabe D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF, Campora L, de Looze F, Downey HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo L, Smetana J, Weckx L, Yeo W, Heineman TC; ZOE-70 Study Group. Cunningham AL, et al. N Engl J Med. 2016 Sep 15;375(11):1019-32. doi: 10.1056/NEJMoa1603800. N Engl J Med. 2016. PMID: 27626517 Free article. Clinical Trial.
Vaccine efficacy against herpes zoster and postherpetic neuralgia was assessed in participants from ZOE-70 and in participants pooled from ZOE-70 and ZOE-50. RESULTS: In ZOE-70, 13,900 participants who could be evaluated (mean age, 75.6 years) received …
Vaccine efficacy against herpes zoster and postherpetic neuralgia was assessed in participants from ZOE-70 and in participants pooled …
The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70.
Boutry C, Hastie A, Diez-Domingo J, Tinoco JC, Yu CJ, Andrews C, Beytout J, Caso C, Cheng HS, Cheong HJ, Choo EJ, Curiac D, Di Paolo E, Dionne M, Eckermann T, Esen M, Ferguson M, Ghesquiere W, Hwang SJ, Avelino-Silva TJ, Kosina P, Liu CS, Markkula J, Moeckesch B, Murta de Oliveira C, Park DW, Pauksens K, Pirrotta P, Plassmann G, Pretswell C, Rombo L, Salaun B, Sanmartin Berglund J, Schenkenberger I, Schwarz T, Shi M, Ukkonen B, Zahaf T, Zerbini C, Schuind A, Cunningham AL; Zoster-049 Study Group. Boutry C, et al. Clin Infect Dis. 2022 Apr 28;74(8):1459-1467. doi: 10.1093/cid/ciab629. Clin Infect Dis. 2022. PMID: 34283213 Free PMC article. Clinical Trial.
BACKGROUND: This ongoing follow-up study evaluated the persistence of efficacy and immune responses for 6 additional years in adults vaccinated with the glycoprotein E (gE)-based adjuvanted recombinant zoster vaccine (RZV) at age 50 years in 2 pivotal efficacy trials (ZOE- …
BACKGROUND: This ongoing follow-up study evaluated the persistence of efficacy and immune responses for 6 additional years in adults vaccina …
Pulp treatment for extensive decay in primary teeth.
Smaïl-Faugeron V, Glenny AM, Courson F, Durieux P, Muller-Bolla M, Fron Chabouis H. Smaïl-Faugeron V, et al. Cochrane Database Syst Rev. 2018 May 31;5(5):CD003220. doi: 10.1002/14651858.CD003220.pub3. Cochrane Database Syst Rev. 2018. PMID: 29852056 Free PMC article. Review.
The comparison between Metapex and zinc oxide and eugenol (ZOE) paste was inconclusive, with no clear evidence of a difference between the interventions for failure at 6 or 12 months (two trials, 62 participants). Similarly inconclusive, there was no clear evidence of a di …
The comparison between Metapex and zinc oxide and eugenol (ZOE) paste was inconclusive, with no clear evidence of a difference betwee …
Recombinant Zoster Vaccine (Shingrix®): A Review in Herpes Zoster.
Syed YY. Syed YY. Drugs Aging. 2018 Dec;35(12):1031-1040. doi: 10.1007/s40266-018-0603-x. Drugs Aging. 2018. PMID: 30370455 Review.
In the pivotal trials in adults aged 50 years (ZOE-50) and 70 years (ZOE-70), RZV significantly reduced the risk of HZ and PHN. Its protective efficacy waned minimally over 4 years and was well preserved in adults aged 70 years. ...
In the pivotal trials in adults aged 50 years (ZOE-50) and 70 years (ZOE-70), RZV significantly reduced the risk of HZ and PHN …
A comparison of calcium hydroxide/iodoform paste and zinc oxide eugenol as root filling materials for pulpectomy in primary teeth: A systematic review and meta-analysis.
Najjar RS, Alamoudi NM, El-Housseiny AA, Al Tuwirqi AA, Sabbagh HJ. Najjar RS, et al. Clin Exp Dent Res. 2019 Mar 4;5(3):294-310. doi: 10.1002/cre2.173. eCollection 2019 Jun. Clin Exp Dent Res. 2019. PMID: 31249711 Free PMC article.
Zinc oxide eugenol (ZOE) has traditionally been used as a root filling material in primary teeth pulpectomy. ...It is challenging to select the appropriate filling materials for primary teeth. ZOE or ZOE/iodoform combined with Ca(OH)(2) appears to be the mate …
Zinc oxide eugenol (ZOE) has traditionally been used as a root filling material in primary teeth pulpectomy. ...It is challenging to …
Menopause is associated with postprandial metabolism, metabolic health and lifestyle: The ZOE PREDICT study.
Bermingham KM, Linenberg I, Hall WL, Kadé K, Franks PW, Davies R, Wolf J, Hadjigeorgiou G, Asnicar F, Segata N, Manson JE, Newson LR, Delahanty LM, Ordovas JM, Chan AT, Spector TD, Valdes AM, Berry SE. Bermingham KM, et al. EBioMedicine. 2022 Nov;85:104303. doi: 10.1016/j.ebiom.2022.104303. Epub 2022 Oct 18. EBioMedicine. 2022. PMID: 36270905 Free PMC article.
INTERPRETATION: Findings from this large scale, in-depth nutrition metabolic study of menopause, support the importance of monitoring risk factors for type-2 diabetes and cardiovascular disease in mid-life to older women to reduce morbidity and mortality associated with oestrogen …
INTERPRETATION: Findings from this large scale, in-depth nutrition metabolic study of menopause, support the importance of monitoring risk f …
Does the METHOD study show that ZOE works?
McCartney M, Cohen D. McCartney M, et al. BMJ. 2024 Aug 2;386:q1720. doi: 10.1136/bmj.q1720. BMJ. 2024. PMID: 39095073 No abstract available.
A Systematic Review and Meta-Analysis of Nonvital Pulp Therapy for Primary Teeth.
Coll JA, Vargas K, Marghalani AA, Chen CY, AlShamali S, Dhar V, Crystal YO. Coll JA, et al. Pediatr Dent. 2020 Jul 15;42(4):256-461. Pediatr Dent. 2020. PMID: 32847665
Success with pulpectomies performed with zinc oxide eugenol [ZOE] and with Endoflas (ZOE plus iodoform plus calcium hydroxide) did not differ from that observed using Vitapex or Metapex (iodoform plus calcium hydroxide; P0.50) after 18 months; however, Endoflas and …
Success with pulpectomies performed with zinc oxide eugenol [ZOE] and with Endoflas (ZOE plus iodoform plus calcium hydroxide) …
Lesion sterilization and tissue repair with chloramphenicol, tetracyline, zinc oxide/eugenol paste versus conventional pulpectomy: A 36-month randomized controlled trial.
Castro M, Lima M, Lima C, Moura M, Moura J, Moura L. Castro M, et al. Int J Paediatr Dent. 2023 Jul;33(4):335-345. doi: 10.1111/ipd.13056. Epub 2023 Feb 12. Int J Paediatr Dent. 2023. PMID: 36719000 Clinical Trial.
The teeth were randomized to the LSTR with CTZ paste group or pulpectomy with ZOE paste group. Clinical and radiographic evaluations were performed at 18, 24, 30 and 36 months. RESULTS: At 36 months, clinical success was 86.4% in LSTR with CTZ paste and 90.9% in pulpectomy …
The teeth were randomized to the LSTR with CTZ paste group or pulpectomy with ZOE paste group. Clinical and radiographic evaluations …
Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials.
Oostvogels L, Heineman TC, Johnson RW, Levin MJ, McElhaney JE, Van den Steen P, Zahaf T, Dagnew AF, Chlibek R, Diez-Domingo J, Gorfinkel IS, Hervé C, Hwang SJ, Ikematsu H, Kalema G, Lal H, McNeil SA, Mrkvan T, Pauksens K, Smetana J, Watanabe D, Weckx LY, Cunningham AL. Oostvogels L, et al. Hum Vaccin Immunother. 2019;15(12):2865-2872. doi: 10.1080/21645515.2019.1627818. Epub 2019 Jun 28. Hum Vaccin Immunother. 2019. PMID: 31216205 Free PMC article. Clinical Trial.
In two pivotal efficacy studies (ZOE-50; ZOE-70), the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy against herpes zoster (HZ).Adults aged 50 or 70 years (ZOE-50 [NCT01165177]; ZOE-70 [NCT01165229]) were randomized to receiv …
In two pivotal efficacy studies (ZOE-50; ZOE-70), the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficac …
1,826 results